drugset / Trial / NCT04376788
Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19
RandomizedParallel-groupOpen-labelTreatment
Summary
The aim of this project is to introduce way for treatment of patients with severe COVID-19 disease with respiratory complications.
Timeline
- Start
- 2020-05-20
- Primary completion
- 2020-07-01
- Completion
- 2020-09-01
Publications
- Background Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, Sharma L. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. JAMA. 2020 Mar 17;323(11):1092-1093. doi: 10.1001/jama.2020.1623.
- Background Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel V, Janke C, Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zwirglmaier K, Zange S, Wolfel R, Hoelscher M. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med. 2020 Mar 5;382(10):970-971. doi: 10.1056/NEJMc2001468. Epub 2020 Jan 30. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylene Blue | Diagnostic / imaging agent | 1 mg/kg | Intravenous |
| Subject | plasma from convalescent patients with COVID-19 | Unknown | 200 ml | Intravenous |